Paradigm of metastasis for malignant melanoma

From Melanocytes to Melanoma: The Progression to Malignancy

Volumn , Issue , 2006, Pages 429-440

  Leong, Stanley P L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

lymphovascular system; Melanoma; metastasis; sentinel nodes

Indexed keywords

EID: 78650441003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-994-3_23     Document Type: Chapter

References (50)

1. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Annal Surg 1997;225(1):1-14.
2. Zettersten E, Shaikh L, Ramirez R, Kashani-Sabet M. Prognostic factors in primary cutaneous melanoma. Surg Clin North Am 2003;83(1):61-75.
3. Clark WH, Elder DE, DuPont G IV, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81(24):1893-1904.
4. Liu V, Mihm MC. Pathology of malignant melanoma. Surg Clin North Am 2003;83(1):31-60.
5. Balch CM, Buzaid AC, Soong S, et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19(16):3635-3648.
6. Reintgen DS, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-767.
7. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol 2002; 9(8):762-770.
8. Slingluff CL Jr, Seigler HF. "Thin" malignant melanoma: risk factors and clinical management. Ann Plast Surg 1992;28(1):89-94.
9. Crowley NJ, Darrow TL, Quinn-Allen MA, Seigler HF. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J Immunol 1991;146(5):1692-1699.
10. Debois J. The Anatomy and Clinics of Metastatic Cancer. Kluwer Academic, Norwell, MA: 2002.
11. Akslen LA, Heuch I, Hartveit F. Metastatic patterns in autopsy cases of cutaneous melanoma. Invasion Metastasis. 1988;8(4):193-204.
12. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135(6):807-810.
13. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am 2003;83(1):109-156.
14. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989;8(2):98-101.
15. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3(6):453-458.
16. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230(4):453-463; discussion 463-455.
17. Leong SP. Sentinel lymph node mapping and selective lymphadenectomy: the standard of care for melanoma. Curr Treat Options Oncol. 2004;5(3):185-194.
18. Leong SP. Selective sentinel lymphadenectomy for malignant melanoma. Surg Clin North Am 2003;83(1):157-185.
19. AJCC. Cancer Staging Manual. 6th ed. Springer, New York, NY: 2003.
20. Leong SP. Paradigm of metastasis for melanoma and breast cancer based on the sentinel lymph node experience. Ann Surg Oncol 2004;11(suppl 3):192S-197S.
21. Leong SP, Kashani-Sabet M, Desmond R, et al. Clinical significance of occult metastatic melanoma to sentinel lymph nodes and other high risk factors based on long-term follow-up. World J Surg 2005;29:683-689.
22. Morton DL, Hoon DS, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238(4):538-549; discussion 549-550.
23. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004;11(Suppl 3):162S-168S.
24. Kretschmer L, Hilgers R, Mohrle M, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004;40(2):212-218.
25. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62(13):3581-3586.
26. Kim CJ, Reintgen DS, Yeatman TJ. The promise of microarray technology in melanoma care. Cancer Control 2002;9(1):49-53.
27. Leong SP. Future perspectives on malignant melanoma. Surg Clin North Am 2003;83(2):453-456.
28. Shivers SC, Li W, Lin J, Stall A, Stafford M, Messina J. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res 2001;158:187-199.
29. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-2826.
30. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004;22(13):2671-2680.
31. Muhlbauer M, Langenbach N, Stolz W, et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res 1999;5(5):1099-1105.
32. Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13(8):2109-2116.
33. Samija M, Juretic A, Solaric M, et al. RT-PCR detection of tyrosinase, gp100, MART1/Melan-A, and TRP-2 gene transcripts in peripheral blood of melanoma patients. Croat Med J 2001;42(4):478-483.
34. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52(1):145-176.
35. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188(2):373-386.
36. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999;99(1):23-33.
37. Nakano H, Tamura T, Yoshimoto T, et al. Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur J Immunol 1997;27(1):215-221.
38. Willimann K, Legler DF, Loetscher M, et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 1998;28(6):2025-2034.
39. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12(2):121-127.
40. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002;2(12):957-964.
41. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000;60(17):4932-4938.
42. Yoshida R, Nagira M, Imai T, et al. EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC. Int Immunol 1998;10(7):901-910.
43. Yoshida R, Nagira M, Kitaura M, Imagawa N, Imai T, Yoshie O. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J Biol Chem 1998;273(12): 7118-7122.
44. Geissmann F, Dieu-Nosjean MC, Dezutter C, et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 2002;196(4):417-430.
45. Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998;161(6): 3096-3102.
46. Gunn MD, Kyuwa S, Tam C, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999;189(3):451-460.
47. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 1998;95(1):258-263.
48. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004;10(7): 2351-2358.
49. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162(6):1951-1960.
50. Leong SP. Selective sentinel lymphadenectomy for malignant melanoma, merkel cell carcinoma, and squamous cell carcinoma. Cancer Treat Res 2005;127:39-76.